Today The Wrapmanager Inc. Sells 46 Shares of Vertex Pharmaceuticals Incorporated (VRTX)

Today The Wrapmanager Inc. Sells 46 Shares of Vertex Pharmaceuticals Incorporated (VRTX)

Wrapmanager Inc. cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.6% during the fourth quarter, Holdings Channel reports. The fund owned 7,271 shares of the pharmaceutical company’s stock after selling 46 shares during the period. Wrapmanager Inc.’s holdings in Vertex Pharmaceuticals were worth $536,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Citizens Financial Group Inc RI increased its stake in Vertex Pharmaceuticals by 27.0% in the second quarter. Citizens Financial Group Inc RI now owns 1,189 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 253 shares during the last quarter. Mycio Wealth Partners LLC increased its stake in Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 18 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Vertex Pharmaceuticals during the third quarter worth $107,000. Paradigm Asset Management Co. LLC increased its stake in Vertex Pharmaceuticals by 20.7% in the second quarter. Paradigm Asset Management Co. LLC now owns 1,450 shares of the pharmaceutical company’s stock worth $125,000 after buying an additional 249 shares during the last quarter. Finally, Global X Management Co. LLC increased its stake in Vertex Pharmaceuticals by 158.6% in the third quarter. Global X Management Co. LLC now owns 1,557 shares of the pharmaceutical company’s stock worth $136,000 after buying an additional 955 shares during the last quarter. Institutional investors and hedge funds own 96.35% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up 3.058% during mid-day trading on Wednesday, reaching $84.755. 956,913 shares of the company’s stock traded hands. The stock’s market capitalization is $21.02 billion. The stock has a 50-day moving average price of $78.04 and a 200-day moving average price of $87.19. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $103.73.

A number of analysts have weighed in on VRTX shares. BMO Capital Markets reiterated a “market perform” rating and set a $88.00 price target on shares of Vertex Pharmaceuticals in a report on Wednesday, November 30th. Oppenheimer Holdings, Inc. started coverage on Vertex Pharmaceuticals in a report on Thursday, December 15th. They set a “market perform” rating for the company. Vetr upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $90.91 price target for the company in a report on Thursday, January 19th. Barclays PLC downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $100.00 to $90.00 in a report on Tuesday, November 29th. Finally, RBC Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 12th. Sixteen research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $106.03.

In other news, Director Joshua S. Boger sold 6,500 shares of the stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $77.75, for a total value of $505,375.00. Following the completion of the sale, the director now directly owns 274,725 shares of the company’s stock, valued at $21,359,868.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Joshua S. Boger sold 8,000 shares of the stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $82.48, for a total transaction of $659,840.00. Following the completion of the sale, the director now directly owns 276,225 shares of the company’s stock, valued at $22,783,038. The disclosure for this sale can be found here. Insiders sold 72,770 shares of company stock worth $5,996,006 over the last quarter. Insiders own 1.90% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Related posts

Leave a Comment